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Abstract
Objective: Identify gene expression profiles associated with OA processes in articular cartilage and determine pathways
changing during the disease process.
Methods: Genome wide gene expression was determined in paired samples of OA affected and preserved cartilage of the
same joint using microarray analysis for 33 patients of the RAAK study. Results were replicated in independent samples by
RT-qPCR and immunohistochemistry. Profiles were analyzed with the online analysis tools DAVID and STRING to identify
enrichment for specific pathways and protein-protein interactions.
Results: Among the 1717 genes that were significantly differently expressed between OA affected and preserved cartilage
we found significant enrichment for genes involved in skeletal development (e.g. TNFRSF11B and FRZB). Also several
inflammatory genes such as CD55, PTGES and TNFAIP6, previously identified in within-joint analyses as well as in analyses
comparing preserved cartilage from OA affected joints versus healthy cartilage were among the top genes. Of note was the
high up-regulation of NGF in OA cartilage. RT-qPCR confirmed differential expression for 18 out of 19 genes with expression
changes of 2-fold or higher, and immunohistochemistry of selected genes showed a concordant change in protein
expression. Most of these changes associated with OA severity (Mankin score) but were independent of joint-site or sex.
Conclusion: We provide further insights into the ongoing OA pathophysiological processes in cartilage, in particular into
differences in macroscopically intact cartilage compared to OA affected cartilage, which seem relatively consistent and
independent of sex or joint. We advocate that development of treatment could benefit by focusing on these similarities in
gene expression changes and/or pathways.
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Introduction
Osteoarthritis (OA) is a degenerative disease of the joints
causing pain and disability for an increasing proportion of the
population thereby imposing a large patient and socio-economic
burden [1,2]. Risk factors for OA include age, sex, joint injury,
obesity, and mechanical stresses. In addition, predisposition to OA
has a considerable genetic component and it has been proposed
that OA can be viewed as a continuum resulting from the
interaction between genetics affecting cartilage extracellular
matrix composition and joint shape and sensitivity to the other
factors mentioned [3,4]. Major efforts are made to identify loci
associated with OA susceptibility to elucidate underlying mecha-
nisms [5]. Treatment options to slow down or reverse the OA
process are still very limited and at the time of diagnosis the
damage is already irreversible. Together, this emphasizes the
importance to increase insight into the disease process and to
identify genes and pathways involved in development of OA. A
way to achieve this is by investigating the pathophysiological
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processes in articular cartilage by means of gene expression
analyses.
Initially, expression profiles were established for cartilage from
knee OA joints in comparison to healthy joints using only a limited
number of genes [6]. More recently, exploratory genome wide
expression profiling has been performed for the intact cartilage of
hip and knee OA joints of patients undergoing joint replacement
surgery compared to non-OA joints either derived from autopsies
or from neck of femur fractures [7,8]. These studies showed that
many genes involved in extracellular matrix (ECM) production as
well as genes involved in ECM degradation or in inflammation
were changed. Together, this resulted in significant enrichment for
genes involved in skeletal development and response to external
stimuli. Although studies that compare healthy cartilage with the
preserved cartilage of joints from OA patients are very useful to
acquire insight into the pathogenetic differences, the findings are
likely biased by confounding factors such as innate differences,
age, and stratification by joint. Moreover, due to the study design
distinction between age-related changes and early or late changes
of OA pathophysiology is hampered.
One of the characteristics of OA is focal loss of articular
cartilage, resulting in areas of degradation as well as areas with a
relative preservation of cartilage thickness and appearance in the
joint. Insight into gene expression specific for the focal areas of
cartilage degradation compared to those in preserved areas can
provide clues towards dynamic changes of genes and pathways
involved in OA pathophysiology independent of confounding
factors such as age. Gene expression profiles of cartilage from OA
affected and macroscopically preserved areas of the same joint
have been determined before, however, in most of these studies
limited numbers of donors (4–5 knee joints) were included [9–11].
As part of the ongoing Research Arthritis and Articular
Cartilage (RAAK) study we set out to perform genome wide
analysis of differential gene expression by comparing 33 pairs of
matched OA affected and preserved cartilage samples, originating
from the same joint of patients that underwent total joint
replacement of either hip or knee. Results provide further insights
in the ongoing OA disease processes in cartilage, in particular into
differences in macroscopically intact cartilage compared to OA
affected cartilage.
Materials and Methods
Ethics statement
Participants of the RAAK study provided written informed
consent. The ongoing RAAK study and its consent procedure is
approved by the institutional ethics review committee (Commissie
Medische Ethiek of the Leiden University Medical Center;
protocol no. P08.239).
Discovery cohort
The RAAK study is aimed at the biobanking of joint materials
as well as mesenchymal stem cells and primary chondrocytes from
patients and controls in the Leiden University Medical Center and
collaborating outpatient clinics in the Leiden area. In the current
study we used paired preserved and OA affected cartilage samples
for 33 donors undergoing joint replacement surgery for primary
OA (22 hips, 11 knees). Characteristics of the donors are shown in
Table S1.
At the moment of collection (within 2 hours following surgery)
tissue was washed extensively with phosphate buffered saline (PBS)
to decrease the risk of contamination by blood. Cartilage was
classified macroscopically and collected separately from OA
affected and preserved regions around the weight-bearing area
of the joint (Figure S1). Classification was done based on
predefined features of OA related damage as described previously
[9,10]: color/whiteness of the cartilage, surface integrity as
determined by visible fibrillation/crack formation, and depth
and hardness of the cartilage upon sampling with a scalpel. Care
was taken to avoid contamination with bone or synovium.
Collected cartilage was snap frozen in liquid nitrogen and stored
at 280uC prior to RNA extraction.
Validation and replication cohort
Validation was performed by RT-qPCR in 8 sample pairs of the
discovery cohort (3 knee and 5 hip) and for replication of the
results we included 28 additional matched sample pairs (20 knee, 8
hip) of similar mean age (shown in Table S1). Sampling
procedures were according to the discovery cohort.
RNA isolation
Cartilage samples were pulverized using a Retsch MM200
under cryogenic conditions. On average 150 mg of pulverized
cartilage was dissolved in 1 ml of Trizol reagent, and mixed
vigorously. After addition of 200 ml of chloroform the sample was
mixed and centrifuged for 15 minutes (16,000 g). The clear
aqueous layer was transferred to a new vial and 1 volume of 70%
ethanol/DEPC-treated water was added to precipitate RNA.
RNA was collected using Qiagen mini columns according to the
manufacturers protocol and quality was assessed using a
Bioanalyzer lab-on-a-chip. RNA integrity numbers above 8 were
considered suitable for microarray analysis.
Microarrays
After in vitro transcription, amplification, and labeling with
biotin-labeled nucleotides (Illumina TotalPrep RNA Amplification
Kit) Illumina HumanHT-12 v3 microarrays were hybridized.
Sample pairs were randomly dispersed over the microarrays,
however each pair was measured on a single chip. Microarrays
were read using an Illumina Beadarray 500GX scanner and after
basic quality checks using Beadstudio software data were analyzed
in R statistical programming language. Intensity values were
normalized using the ‘‘rsn’’ option in the Lumi-package and
absence of large scale between-chip effects was confirmed using
the Globaltest-package in which the individual chip numbers were
tested for association to the raw data [12]. After removal of probes
that were not reliably detected (detection P.0.05 in more than
50% of the samples) a paired t-test was performed for the
remaining 13277 probes comprising 11421 unique genes on all
sample pairs while adjusting for chip (to adjust for possible batch
effects) and using multiple testing correction as implemented in the
‘‘BH’’ (Benjamini and Hochberg) option in the Limma-package.
Analyses for differential expression between OA and healthy and
between preserved and healthy cartilage was performed likewise,
adjusting in addition for sex and for age.
Gene expression profiles of the samples have been deposited in
NCBI’s Gene Expression Omnibus [13] and are accessible
through GEO Series accession number GSE57218.
Quantitative reverse transcription PCR (RT-qPCR)
0.5 mg of total RNA was processed with the First Strand cDNA
Synthesis Kit according to the manufacturer’s protocol (Roche
Applied Science) and RT-qPCR was performed for the 19 genes
showing at least 2-fold expression differences in the microarray
analysis (Taqman gene expression assays used are listed in Table
S2) using the Biomark 96.96 Dynamic Arrays Fluidigm RT-qPCR
platform [14]. Relative gene expressions were calculated with the
Large Scale Gene Expression Profiling of OA Cartilage.
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22DDCt method [15], using household gene Beta Actin (ACTB)
expression as internal standard.
Immunohistochemistry and staining analysis
For histological examination, joints were fixed using a 4%
formaldehyde solution. Subsequently, samples were decalcified
using a 10% EDTA solution and embedded in paraffin. Sections
(5 mm) adjacent to the collected area were stained using
hematoxilin and eosin (H&E) and toluidine blue. Immunohisto-
chemistry was performed for SERPINE1 (mouse monoclonal
antibody from American Diagnostica Inc.) without antigen
retrieval and for CD55 (rabbit polyclonal antibody from Santa
Cruz Biotechnology Inc.) with heat antigen retrieval (0,01 M
Citratebuffer pH=6.0) as described previously [16].
Quantification of OA related cartilage damage was scored by 2
observers (JVMGB and YFMR) according to Mankin et al [17].
Quantification of SERPINE1 expression was performed by
scoring staining of chondrocytes in the superficial, middle, and
deep cartilage layer with a score of 0 (no staining), 1 (moderate
staining), or 2 (strong staining). Using Generalized Estimating
Equations, scores were summed and used as a predictor variable
with Mankin score as outcome whilst correcting for sex and age of
each donor.
Pathway analysis and protein-protein interaction
Gene enrichment among the 1717 genes showing significant
differential expression was performed with the Database for
Annotation, Visualization and Integrated Discovery (DAVID) tool
[18] selecting for biological processes identified in the Gene
Ontology database (GOTERM_BP_FAT in the options menu
implemented in DAVID), selecting for cell compartment (GO-
TERM_CC_FAT), or selecting for molecular function (GO-
TERM_MF_FAT) and using the microarray background (Hu-
manHT-12_V3_0_R2_11283641_A). Pathways with P#0.05
after correction for multiple testing according to Bonferroni were
considered significant (Bonferroni corrections were performed by
multiplying the raw P-values with the number of genes included in
the analysis).
Enrichment in protein-protein interactions among the signifi-
cant genes was analyzed with the Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING) 9.0 [19] available online.
Literature based candidate genes
Based on selected publications of genome wide association study
meta-analyses [20–29] we investigated our expression dataset for
evidence of differential gene expression of the reported significant
candidate genes.
Results
Differential expression between preserved and OA
affected cartilage
To identify genes with changed expression in response to
ongoing OA processes genome wide expression profiles were
generated for preserved and OA affected cartilage of the same
joint of 33 donors. Characteristics of the donors are shown in
Table S1. Males (N=13) and females (N= 20) included in the
study were aged between 54 and 80 years (mean age: 66.2). In
total, 22 patients received a hip replacement and 11 patients
underwent total knee replacement. Among all OA joints included
in this study (61 in total), 28 pairs were randomly selected to assess
the Mankin scores of preserved and affected areas. Mankin scores
were significantly higher in the samples macroscopically designat-
ed as ‘OA affected’ as compared to sections distinguished as
‘preserved’ (mean Mankin score 7.8 vs. 4.7, respectively,
P=461024, paired t-test) and as a result gene expression
differences can be directly linked to these differences in Mankin
scores.
After normalization and correction for multiple testing,
significant differential expression between the OA affected and
preserved cartilage was identified for 1893 probes, representing
1717 unique genes (Table S3). Among the 1717 unique genes 19
were differently expressed with fold-changes of 2 and higher
(Table 1). Notably, 14 of these were up-regulated in OA as
compared to preserved cartilage and only 5 were down-regulated.
Overall, 748 (44%) of the differentially expressed genes were up-
regulated. Larger fold changes were observed in expression of
genes well known for their association with OA cartilage such as
tumor necrosis factor alpha-induced protein 6 (TNFAIP6 also
known as TSG-6, 2.9-fold up in OA cartilage; P=4.461028),
cytokine receptor-like factor 1 (CRLF1, 3-fold up in OA cartilage;
P=4.461028), and Wnt-inhibitor frizzled related protein beta
(FRZB, 2.5-fold down in OA cartilage; P=1.361026). A notable
gene highly up-regulated in OA cartilage was neuronal growth
factor (NGF, 2.3-fold up; P=3.461027).
Validation of the 19 genes with fold-changes of 2 or higher in 8
sample pairs used in the microarray analyses by means of RT-
qPCR showed similar effect sizes and directions as those found in
the microarray analysis (Table S5). Replication performed in an
additional set of 28 independent preserved and affected cartilage
sample pairs also showed comparable effect sizes and directions
and, except for cysteine-rich secretory protein LCCL domain-
containing 1 precursor (CRISPLD1), all genes were significantly
different expressed (Table 1). Individual expression boxplots of the
replicated genes are shown in Figure S2.
Expression profiles of genes with fold-changes of 2 and higher
were analyzed for association with Mankin score as a grade of
disease severity (Table 2). Almost all genes associated with Mankin
score, except for COL9A1, HBA2 and HBB. To further
characterize expression of the 19 genes with highest fold changes
in OA affected cartilage, we investigated whether the observed
changes were either joint or sex specific. As shown in Table 2, for
most of the genes fold changes of the (joint or sex) stratified
analyses were highly comparable and not statistically different
from those of the discovery analysis. However, increased
expression of pregnancy-associated plasma protein A (PAPPA)
was significantly less pronounced in knee OA (1.3-fold increase)
than in hip OA (2.6-fold increase).
In addition to the gene expression profiles of preserved and OA
affected cartilage, gene expression profiles were also generated for
7 healthy cartilage (characteristics of the donors are shown in
Table S1) and explored for the 19 genes. For most of these 19
genes we did not find significant differences between healthy and
preserved cartilage. However, when analyzing the trend of the
differences between healthy, preserved and OA affected cartilage
we did find a significant linear effect on the expression of most
genes. In contrast, expression changes of CRISPLD1 and
COL9A1 in healthy versus preserved cartilage were not significant
and appeared to be increased while the expression in preserved
versus OA affected cartilage was found to be decreased (Figure
S3).
Functional annotation of genes differently expressed in
OA affected cartilage
To investigate whether the genes differently expressed between
preserved and OA affected cartilage belonged to specific pathways,
we used the online functional annotation tool DAVID. Seven GO-
terms referring to 6 independent pathways were identified
Large Scale Gene Expression Profiling of OA Cartilage.
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(Table 3). The most significant GO-term was observed for
‘‘skeletal system development’’. This term captured several of
the genes with fold-changes of 2 or higher (e.g. FRZB and
TNFRSF11B). Furthermore, of note was the GO-term referring
to ‘‘extracellular matrix organization’’ including decorin (DCN)
and several collagens (e.g. COL1A2, COL2A1, COL3A1). When
analyzing for enrichment using the cellular compartment option,
most significant GO-term was ‘‘extracellular matrix’’, and
analyzing for molecular function showed genes involved in
‘‘copper ion binding’’ and ‘‘glycosaminoglycan binding’’ to be
significantly enriched (Table 3).
Among the 19 genes that were highly changed in OA affected
cartilage (at least 2-fold), 3 pathways were significantly enriched
with lowest P-value for GO-term ‘‘response to wounding’’
(Table 4), which included the genes TNFAIP6, SERPINE2,
and CD55. When analyzing for interaction among proteins
encoded by these genes using STRING, we found significant
enrichment for protein-protein interactions (P=4.7610210) in
which fibronectin-1 (FN1) seemed to play a central role
considering that 6 of the 19 proteins were found to relate to
FN1 (Figure 1).
Immunohistochemical assessment of proteins encoded
by genes identified in the microarray analysis
In addition to differential expression of proteins encoded by
genes found in the microarray analysis, immunohistochemical
(IHC) staining provides insight in expression pattern and
localization of differentially expressed genes in the different
cartilage layers. Therefore, as a proof of principal, IHC was
performed for SERPINE1 and CD55. Figure 2 shows represen-
tative sections for the staining of preserved (P) versus OA affected
cartilage, with Figure 2A and B showing an example of the H&E
and Toluidine blue staining respectively (upper panel: 4x
magnification, lower panel 20x magnification).
Immunohistochemistry for SERPINE1 showed that the protein
is expressed in chondrocytes and differential expression between
OA and preserved cartilage at the protein level was very
pronounced (Figure 2C). In OA affected cartilage, SERPINE1
was not only expressed in the superficial layer, but also in the
middle layer. In the most affected parts, we even observed
SERPINE1 protein expression in chondrocytes residing in the
deep zone. In addition, increasing matrix staining of SERPINE1
was observed with increasing OA affection state. We performed a
quantification of the staining as described in Materials and
Methods, and statistical analysis showed a significant difference
between protein abundance in OA and preserved cartilage
(P=2.461024). The expression difference seemed to correlate
mostly with toluidine blue staining, and thus with the level of
proteoglycan constituents of chondromucin aggregates in the
samples (P=2.961029).
CD55 protein expression was most pronounced in the
superficial layer, with higher levels in the more OA affected zones
of the cartilage, while hardly any CD55 positive cells were
detected in the deep layer (Figure 2D). The differences, however,
were more subtle than for SERPINE1 and the range in the
quantification did not allow for statistical analysis.
Prioritization of genes residing in compelling genome
wide association signals
In order to explore whether genes identified by genome wide
association studies are active in cartilage and/or change in
response to the OA process, we screened for differential expression
of genes originating from recently published large scale meta
analyses on OA (Table 5). Sixteen of the 29 genes selected were
well detected in the microarray (Pdetection#0.05) and from these, 8
were significantly different between OA and preserved cartilage.
Most genes showed only modest expression changes. Of note was
differential expression of the HMG-box transcription factor 1
(HBP1) gene, identified in the Rotterdam study [24], which
showed 1.1-fold up-regulation in OA cartilage (P=2.061023).
Discussion
As part of the RAAK study we compared genome wide
expression levels between preserved and OA affected cartilage of
the same joint from 33 donors. Such a paired study design allows
the detection of genes specifically involved in the OA pathophys-
iological process, independent of inter-individual or age-related
confounding factors as also reflected by the highly comparable
differential gene expression patterns when stratifying according to
joint and sex. After correction for multiple testing 1717 unique
genes showed significant differential expression, of which 19 genes
had a fold-change of 2 or higher. In an independent paired
cartilage sample set, differential expression was confirmed for 18
genes by RT-qPCR. For most of these genes, except HBA2, HBB,
and COL9A1, expression associated with disease severity as
determined by scoring according to Mankin [17], and OA-
associated increase in protein expression for 2 genes (CD55 and
SERPINE1) was demonstrated by immunohistochemistry.
We confirmed several genes previously identified in within-joint
analyses for OA affected versus preserved cartilage as well as
analyses comparing preserved cartilage from OA affected joints
versus healthy cartilage such as the inflammatory genes CD55 [8],
PTGES and TNFAIP6 [11]. This overlap is noteworthy since in
our analysis considerably more samples were included. A large
sample size increases power to detect replicable findings and
allows detection of differences that were previously missed or more
subtle. Our data thus indicate that at least a number of genes are
consistently involved in the OA disease process despite the
appreciated heterogeneous pathophysiology. Another gene present
among the top genes and highly up-regulated in OA affected
cartilage was the tumor necrosis factor receptor superfamily 11b
(TNFRSF11B) gene encoding osteoprotegerin. Very recently we
reported in this protein on a gain of function mutation likely causal
in a family with early onset OA with chondrocalcinosis [30]. In
this respect, the up-regulated expression, could contribute to
respective mineralization of the cartilage and eventually formation
of bone, a major hallmark of the ongoing osteoarthritis disease
process.
Studies comparing intact cartilage with OA affected cartilage of
the same joint allow detection of gene expression changes specific
to the ongoing OA pathophysiological processes independent of
confounding factors such as sex and age and joint as was also
demonstrated by the highly comparable results of our stratified
analysis. Identification of such genes commonly changing during
OA independent of joint site or sex could be very useful with
respect to drug development. On the other hand, differences
identified between the intact cartilage derived from patients
undergoing joint replacement surgery and healthy cartilage of
independent joints are of a cross-sectional nature and provide
information on innate differences among OA patients as well as
genes changing during OA. Therefore, genes overlapping among
the different studies may be of interest to better understand
dynamic changes during onset and ongoing OA. A notable
example was the expression of the COL9A1 gene that was higher
in preserved as compared to healthy cartilage (3.6-fold), but was
subsequently decreased in the OA affected cartilage (Figure S3).
Large Scale Gene Expression Profiling of OA Cartilage.
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Although we acknowledge the fact that the included 7 healthy
cartilage samples had a large age-range, our results are in line with
the findings of Karlsson et al [8] and Xu et al [7] showing
increased expression of COL9A1 in cartilage from patients
undergoing joint replacement surgery in comparison to healthy
cartilage. This altered direction of effect in ongoing OA may
explain the fact that COL9A1 was found not to be associated with
Mankin score and suggests that it is mainly involved in the initial
response of the chondrocyte to cartilage damage. Gene enrich-
ment analyses performed with all significant genes showed
especially that genes involved in the skeletal development were
changed in OA affected as compared to preserved cartilage.
Notably, this is in accordance with observations from Xu et al [7]
who found enrichment of genes involved in skeletal development
by comparing healthy cartilage versus cartilage of OA affected
joints, suggesting that this is a pathway commonly affected in OA
cartilage, both in the initiation phases as well as in ongoing OA.
The fact that genes involved in skeletal development (e.g. FRZB
and TNFRSF11B, but also OSTF1, FGFR3, and IGFBP3; Table
S3) change during ongoing OA processes confirms the hypothesis
that OA chondrocytes lose their maturational arrested phenotype,
specific for articular cartilage, towards their end-stage differenti-
ation, resembling growth plate during skeletal development [3].
As reviewed by Barter and Young [31], gene expression
differences in OA affected tissues may originate from changes in
epigenetic control mechanisms. More recently, a comparison
between the methylome of hip OA cartilage with cartilage of non-
OA hips indeed showed more than 5000 differentially methylated
loci whereas the annotated genes were mainly involved in
pathways related to skeletal development [32] similar to the
current and previous transcriptomic analyses [7]. Although direct
association between such changes in DNA methylation and
respective gene expression remains to be demonstrated, the
skeletal developmental processes appear to consistently mark
ongoing OA pathophysiology.
Recently, a GWAS for hand OA identified a locus in the
aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) gene
[33]. Expression of ALDH1A2 was shown to be allele dependent
and with decreased expression in OA affected cartilage. Despite
this and other recent successes of genome wide association studies
[24,28] a variety of the identified signals indicate chromosomal
regions without obvious OA candidate genes or regions of high
linkage disequilibrium with many relative unknown genes [24,28].
Table 4. Gene enrichment analysis.
Term Count Pct Enr. Pval Pvaladj FDR
GO:0009611,response to wounding 6 31.58 8.87 2.96E-04 5.63E-03 3.94E-01
GO:0001501,skeletal system development 5 26.32 12.10 4.95E-04 9.40E-03 6.58E-01
GO:0006954,inflammatory response 5 26.32 12.06 5.01E-04 9.51E-03 6.65E-01
Pathway analysis considering the biological processes option in DAVID (GOTERM_BP_FAT) using the genes from Table 1 with at least 2-fold expression difference
between OA affected and preserved cartilage (GO-Term: GO-terms within the different clusters; Count: number of genes identified for the respective GO-term; Pct:
percentage of genes from total number of genes tested; Enr.: fold enrichment of indicated pathway; Pval: P-value; Pvaladj: adjusted P-value; FDR: false discovery rate).
doi:10.1371/journal.pone.0103056.t004
Figure 1. Protein-protein interaction between the genes with expression changes of at least 2-fold (Table 1) as determined with
STRING.
doi:10.1371/journal.pone.0103056.g001
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Here, we provide a means of exploring the overall expression and
behavior during disease in cartilage. Although OA should be
considered a ‘whole joint disease’ [2] and expression profiles of
other OA affected joint tissues such as those performed recently in
subchondral bone [34] are highly valuable, expression profiles in
OA cartilage could serve as one of the selection criteria to
prioritize genes for functional follow-up studies and research
directed at understanding pathophysiological mechanisms of OA
and drug design. In our cartilage dataset, we found differential
expression for several of the genes, among which PAPPA was
most significant (P=1.161026), positionally localized in close
neighborhood of one the arcOGEN genome wide hits: rs4836732
within the ASTN2 gene. The exact linkage disequilibrium across
this locus needs to be further explored. We also found HBP1, at
the chr7q22 locus, to be differently expressed, although with small
effect size in the OA versus preserved comparison (1.1-fold higher
in OA affected cartilage). When comparing diseased cartilage (OA
affected as well as macroscopically intact cartilage) with healthy
cartilage we observed a much stronger and opposite direction of
effects: healthy versus OA and healthy versus preserved both
showed 1.4-fold lower expression (Table S4) in accordance with a
previous study by Raine et al. showing increased expression of
HBP1 in OA affected cartilage [35]. Given that HBP1 resides in
the 7q22 gene cluster [24] results mark this gene as most likely
candidate for further functional follow-up investigations.
Although MCF2L (MCF.2 cell line derived transforming
sequence-like), a gene previously identified in GWA as an OA
susceptibility gene [22], was not well-detected in the microarray
analysis, the significant increased expression of neuronal growth
factor (NGF) is worth mentioning in this respect. Neurotrophin-3
(NT3), another member of the NGF-family of proteins, enhances
migration of premyelinating Schwann cells via Dbs/MCF2L [36],
possibly implicating nociception in OA. Interestingly, antibodies
generated against NGF or its receptor have been used successfully
to treat OA patients and effectively reduced their pain [37]. The
fact that NGF was not identified previously by comparing healthy
with OA affected cartilage [7,8] suggests that NGF may be more
specific for the ‘‘late’’ OA process. Alternatively, selection of
druggable targets from early-responsive genes that start changing
Figure 2. Representative slides of immunohistochemical staining. A) H&E staining. B) Toluidine blue staining. C) SERPINE1. D) CD55
(magnification 20x; insets show larger overview at magnification 4x; white scale bars indicate 50 mm and 200 mm, respectively). The left panels show
preserved cartilage area (P) and the right panels show the OA affected cartilage area (OA).
doi:10.1371/journal.pone.0103056.g002
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before damage is irreversible could be more eligible to effectively
slow-down or stop the OA process.
The sample collection is performed by well-trained lab
personnel, however, we cannot exclude the possibility of minor
contamination with bone tissue. In this respect, it is of note that
several cartilage-specific genes (e.g. decorin or DCN, collagen type
2 A1 (COL2A1), cartilage intermediate layer protein (CILP), and
cartilage oligomeric matrix protein (COMP) were amongst the 100
genes with highest levels of expression in the dataset while no
bone-specific genes (e.g. COL1A1, COL1A2, TNFRSF11B, and
bone sialoprotein II or IBSP) were identified here.
In conclusion, our results add to the insight into the ongoing
pathological processes in OA cartilage by the identification of
different gene expression patterns depending on OA severity as
determined by Mankin score. This large scale analysis of joint-
matched OA affected and preserved cartilage seems to hint at
relatively consistent changes in gene expression during OA
development. We think research and development of OA
treatment could benefit by focusing on these similarities in gene
expression changes and/or pathways.
Supporting Information
Figure S1 Typical example of hip (A) and knee (B) joint
with areas of macroscopically preserved (arrow head)
and OA affected cartilage (arrow; white scale bars
indicate 500 mm). Insets show detail of preserved (right) and
OA affected area (left), in A separated by a dashed line (scale bar
inset in B: 250 mm).
(TIF)
Figure S2 Individual box plots per status for genes
validated by RT-qPCR.
(TIF)
Figure S3 Relative changes in gene expression levels in
preserved and OA affected cartilage relative to healthy
Table 5. Genes identified in robust genome wide approaches with fold-changes and P-values for OA versus preserved cartilage
(OA vs P).
OA vs P
Gene Ref Joint published FC Pval
ASTN2 [28] Hip&Knee – –
BCAP29 [24] Knee 1.1 1.761022
BTNL2 [26] Knee – –
C6ORF130 [27] Hip&Knee 0.88 1.661023
CDC5L [28] Hip&Knee – –
CHST11 [28] Hip&Knee – –
COG5 [24] Knee 0.98 2.161021
COL11A1 [27] Hip&Knee 0.94 4.561021
DOT1L [20] Hip – –
DUS4L [24] Knee – –
DVWA [25] Knee – –
FILIP1 [28] Hip&Knee – –
FTO [28] Hip&Knee 1.0 8.561021
GDF5 [21] Hip&Knee 1.1 4.361022
GLT8D1 [28] Hip&Knee 1.0 3.061021
GNL3 [28] Hip&Knee 1.1 4.661022
GPR22 [24] Knee – –
HBP1 [24] Knee 1.1 2.061023
HLA-DQB1 [26] Knee – –
KLHDC5 [28] Hip&Knee 1.0 4.861021
MCF2L [22] Hip&Knee – –
MICAL3 [27] Hip&Knee – –
NCOA3 [23] Hip 0.93 7.961023
PAPPA [28] Hip&Knee 2.1 1.161026
PRKAR2B [24] Knee 1.0 9.961021
PTHLH [28] Hip&Knee 1.4 1.861023
SENP6 [28] Hip&Knee 1.1 3.361021
SUPT3H [28] Hip&Knee 1.0 6.161021
TP63 [28] Hip&Knee – –
VEGF [29] Hip 1.0 4.561021
(Ref: reference, where indicated gene was published as OA susceptibility gene; Pval: nominal P-value; FC: fold change; –: not detected on microarray).
doi:10.1371/journal.pone.0103056.t005
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cartilage for the 19 genes with at least 2-fold difference in
the OA versus preserved analysis (note that the line does
not imply continues changes given the fact that the
healthy cartilage was derived from independent donors).
(TIF)
Table S1 Characteristics of OA donors included in the
microarray analyses (discovery) and in the replication
and characteristics of the healthy donors included in the
microarray analysis.
(XLSX)
Table S2 Taqman probes used in the fluidigm RT-
qPCR experiment.
(XLSX)
Table S3 Genes significantly differently expressed
between OA and preserved cartilage in microarray
analysis of 33 paired OA affected and preserved samples
(FC: fold change; Pval: P-value; highlighted in yellow the
genes that are also significantly different in the healthy
versus preserved cartilage comparison).
(XLSX)
Table S4 Genes significantly differently expressed
between preserved and healthy cartilage (FC: fold
change; Pval: P-value).
(XLSX)
Table S5 Results of the validation of the genes with at
least 2-fold significant differential expression between
OA affected and preserved cartilage in the microarray
analyses (Dir: direction of effects; FC: fold change; Pval:
P-value).
(XLSX)
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